← Leaderboards
Andrew L Kung
Dana-Farber Cancer Institute
$5,571,759
Attributed
$7,440,944
Total exposure
7
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $749.3K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,440,944 · 7
By mechanism
U01$3,652,183 · 1
R01$1,679,994 · 1
R21$1,256,994 · 3
K01$765,585 · 1
R03$86,188 · 1
Top collaborators
- Filemon S Dela Cruz5 shared
- Kimberly Stegmaier2 shared
Most similar at Dana-Farber Cancer Institute
Same institution · by research overlap
- Kimberly Stegmaier$26,925,503
- William C Hahn$46,384,528
- Karl Hsu$475,430
- Scott A Armstrong$21,470,003
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsBaseProteinsTranslationsIn VitroGene ExpressionResponseDrug DevelopmentCell LineGenesGrowthTranscription FactorXenograft ProcedureProgramsGenetic TranscriptionEmerging TechnologiesClinical TrialsGenomicsCancer ModelCellsModificationMethodologyTumorIn Vivo
Grant awards (25)
Pediatric Preclinical In Vivo Testing Center for Pediatric Sarcoma and Other Solid Tumors$727,406
U01 · FY2025 · CA · contact PI
Pediatric Preclinical In Vivo Testing Center for Pediatric Sarcoma and Other Solid Tumors$730,032
U01 · FY2024 · CA · contact PI
Pediatric Preclinical In Vivo Testing Center for Pediatric Sarcoma and Other Solid Tumors$730,032
U01 · FY2023 · CA · contact PI
Pediatric Preclinical In Vivo Testing Center for Pediatric Sarcoma and Other Solid Tumors$715,431
U01 · FY2022 · CA · contact PI
Pediatric Preclinical In Vivo Testing Center for Pediatric Sarcoma and Other Solid Tumors$749,282
U01 · FY2021 · CA · contact PI
Leveraging in vivo models to identify epigenetic vulnerabilities in leukemia$198,452
R21 · FY2016 · CA · contact PI
Leveraging in vivo models to identify epigenetic vulnerabilities in leukemia$23,547
R21 · FY2016 · CA · contact PI
Leveraging in vivo models to identify epigenetic vulnerabilities in leukemia$174,000
R21 · FY2015 · CA · contact PI
Functionizing the epigenome in Ewing sarcoma$163,560
R21 · FY2013 · CA · contact PI
Targeting the ETS Transcription Factor Rearrangement EWS/FLI in Ewing's Sarcoma$42,438
R03 · FY2013 · DA · contact PI
Functionizing the epigenome in Ewing sarcoma$228,375
R21 · FY2012 · CA · contact PI
Transcription factor and epigenetic regulation of hypoxic gene expression$188,704
R01 · FY2012 · GM · contact PI
Transcription factor and epigenetic regulation of hypoxic gene expression$133,516
R01 · FY2012 · GM · contact PI
Targeting the ETS Transcription Factor Rearrangement EWS/FLI in Ewing's Sarcoma$43,750
R03 · FY2012 · DA · contact PI
Transcription factor and epigenetic regulation of hypoxic gene expression$335,194
R01 · FY2011 · GM · contact PI
A novel probe for imaging apoptosis$254,023
R21 · FY2011 · EB · contact PI
Transcription factor and epigenetic regulation of hypoxic gene expression$338,580
R01 · FY2010 · GM · contact PI
A novel probe for imaging apoptosis$215,037
R21 · FY2010 · EB · contact PI
Transcription factor and epigenetic regulation of hypoxic gene expression$342,000
R01 · FY2009 · GM · contact PI
Transcription factor and epigenetic regulation of hypoxic gene expression$342,000
R01 · FY2008 · GM · contact PI
Hypoxia inducible transcription in antitumor strategies$157,437
K01 · FY2005 · CA
Hypoxia inducible transcription in antitumor strategies$157,437
K01 · FY2004 · CA
Hypoxia inducible transcription in antitumor strategies$157,437
K01 · FY2003 · CA
Hypoxia inducible transcription in antitumor strategies$157,437
K01 · FY2002 · CA
Hypoxia inducible transcription in antitumor strategies$135,837
K01 · FY2001 · CA